The FDA has approved Crysvita for the treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in patients aged ≥2 years.
A EULAR task force developed recommendations for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy.
A slightly increased risk for developing certain cancers was seen in patients with psoriasis.
Researchers evaluated the risk for nonmelanoma skin cancer in patients receiving anti-tumor necrosis factor (TNF) inhibitors vs those who did not receive anti-TNFs.
Interleukin (IL) therapy for the treatment of rheumatologic diseases may increase the risk for serious infections, opportunistic infections, and cancer.
In patients with rheumatologic diseases, treatment with interleukin inhibitors may increase the risk of serious infections, opportunistic infections, and cancer, according to a systematic review and meta-analysis published in JAMA Network Open.
The guideline includes strategies to identify patients with nonmetastatic cancer who may be at a higher risk for osteoporotic fractures.
Compared with the general population, there is an increased risk for certain cancers in patients with rheumatoid arthritis (RA) in Singapore.
In this expert interview, Sasha Bernatsky, MD, PhD, and Michelle Petri, MD, MPH, discuss the risk of non-Hodgkin lymphoma in SLE.
Research shows that younger survivors are at increased risk of serious long-term health conditions resulting from thyroid cancer treatments.
